[go: up one dir, main page]

NO20073889L - Fast farmasoytisk sammensetning omfattende Valsartan - Google Patents

Fast farmasoytisk sammensetning omfattende Valsartan

Info

Publication number
NO20073889L
NO20073889L NO20073889A NO20073889A NO20073889L NO 20073889 L NO20073889 L NO 20073889L NO 20073889 A NO20073889 A NO 20073889A NO 20073889 A NO20073889 A NO 20073889A NO 20073889 L NO20073889 L NO 20073889L
Authority
NO
Norway
Prior art keywords
valsartan
pharmaceutical composition
solid pharmaceutical
valsartan particles
particles
Prior art date
Application number
NO20073889A
Other languages
English (en)
Norwegian (no)
Inventor
Marija Rangus
Miha Vrbinc
Janika Slanc Vovk
Silvo Zupancic
Franci Bevec
Lidija Cernosa
Original Assignee
Krka Dd Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35966966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073889(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP04030782A external-priority patent/EP1674080A1/fr
Application filed by Krka Dd Novo Mesto filed Critical Krka Dd Novo Mesto
Publication of NO20073889L publication Critical patent/NO20073889L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20073889A 2004-12-24 2007-07-24 Fast farmasoytisk sammensetning omfattende Valsartan NO20073889L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030782A EP1674080A1 (fr) 2004-12-24 2004-12-24 Composition pharmaceutique comprenant du valsartan
EP05004433 2005-03-01
PCT/EP2005/013963 WO2006066961A1 (fr) 2004-12-24 2005-12-23 Composition pharmaceutique solide comprenant du valsartan

Publications (1)

Publication Number Publication Date
NO20073889L true NO20073889L (no) 2007-09-24

Family

ID=35966966

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073889A NO20073889L (no) 2004-12-24 2007-07-24 Fast farmasoytisk sammensetning omfattende Valsartan

Country Status (16)

Country Link
US (1) US20080102120A1 (fr)
EP (2) EP1833464A1 (fr)
CN (1) CN101087589B (fr)
AU (1) AU2005318365B2 (fr)
CA (1) CA2592091A1 (fr)
DK (1) DK2033629T3 (fr)
EA (2) EA012392B1 (fr)
ES (1) ES2397552T3 (fr)
HR (1) HRP20130033T1 (fr)
ME (1) ME01453B (fr)
NO (1) NO20073889L (fr)
PL (1) PL2033629T3 (fr)
PT (1) PT2033629E (fr)
RS (1) RS52607B (fr)
SI (1) SI2033629T1 (fr)
WO (1) WO2006066961A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897537A1 (fr) * 2006-09-04 2008-03-12 Novartis AG Composition contenant un antagoniste des récepteurs de l'angiotensine II
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
WO2008076780A2 (fr) * 2006-12-14 2008-06-26 Isp Investments Inc. Valsartan amorphe et production de celui-ci
TR200703568A1 (tr) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
WO2009113091A2 (fr) * 2008-01-24 2009-09-17 Usv Limited Compositions pharmaceutiques contenant du valsartan
WO2010104485A2 (fr) * 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan
WO2011102702A2 (fr) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
CN102119912A (zh) * 2011-01-25 2011-07-13 南京白敬宇制药有限责任公司 一种非水溶性药物缓释制剂的制备方法
CN102204907A (zh) * 2011-03-31 2011-10-05 北京赛科药业有限责任公司 一种含缬沙坦的药物组合物及其制备方法
WO2013098576A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique de valsartan à libération immédiate
WO2013098578A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104887640B (zh) * 2015-06-30 2017-12-19 昆明医科大学 一种含有缬沙坦的固体药物组合物
US20210267908A1 (en) * 2020-03-02 2021-09-02 Mankind Pharma Ltd. Pharmaceutical compositions of rivaroxaban
CN112098408B (zh) * 2020-09-14 2022-12-09 湖北亿纬动力有限公司 一种羧甲基纤维素钠溶解效果的检测方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DK1588706T3 (da) 1998-12-23 2012-01-16 Novartis Ag Valsartantablet
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6211217B1 (en) * 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AR032316A1 (es) * 2000-04-12 2003-11-05 Novartis Ag Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
HUP0301390A3 (en) 2000-06-22 2005-04-28 Novartis Ag Oral pharmaceutical composition containing valsartan
US20030207930A1 (en) * 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
ES2290429T3 (es) * 2002-01-17 2008-02-16 Novartis Ag Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep.
CN1726030A (zh) * 2002-12-18 2006-01-25 诺瓦提斯公司 缬沙坦与cox－2抑制剂的组合
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1556363A2 (fr) 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Procede de preparation du valsartan et de ses intermediaires
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid

Also Published As

Publication number Publication date
US20080102120A1 (en) 2008-05-01
EP2033629B1 (fr) 2012-11-14
EP1833464A1 (fr) 2007-09-19
DK2033629T3 (da) 2013-02-04
EA200900646A1 (ru) 2009-10-30
EP2033629A1 (fr) 2009-03-11
HRP20130033T1 (hr) 2013-02-28
AU2005318365A1 (en) 2006-06-29
PT2033629E (pt) 2013-01-24
EA015108B1 (ru) 2011-06-30
CN101087589B (zh) 2013-01-30
ME01453B (me) 2014-04-20
WO2006066961A1 (fr) 2006-06-29
CN101087589A (zh) 2007-12-12
CA2592091A1 (fr) 2006-06-29
SI2033629T1 (sl) 2013-01-31
AU2005318365B2 (en) 2011-02-03
EA012392B1 (ru) 2009-10-30
ES2397552T3 (es) 2013-03-07
RS52607B (sr) 2013-04-30
PL2033629T3 (pl) 2013-04-30
EA200701107A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
NO20073889L (no) Fast farmasoytisk sammensetning omfattende Valsartan
WO2005082056A3 (fr) Structures d'enveloppes reutilisables et procedes
SG155884A1 (en) Coating composition
WO2007053696A3 (fr) Inhibition de la replication du virus de la grippe par interference arn
WO2011060304A3 (fr) Laveurs d'oxygène, compositions comprenant les laveurs, et articles réalisés à partir des compositions
WO2012066308A3 (fr) Compositions
CL2008002779A1 (es) Composicion fungicida para controlar hongos nocivos fitopatógenos que comprende una cepa seleccionada de bacillus substilis y cepas de bacillus pumilus, o mutante de estas cepas; en combinación con un antigúngico químico
WO2011045544A3 (fr) Procede de caracterisation d'au moins un microorganisme par spectrometrie de masse
BRPI0512326A (pt) composições compreendendo anfotericina b, métodos e sistemas
NO20076360L (no) Dengue serotype 2 attenuert stamme
WO2008035221A3 (fr) Composition de béton présentant un retrait réduit
MX2009008250A (es) Composiciones para aplicacion topica que comprenden un peroxido y retinoide.
EA200702562A1 (ru) Способ получения хлоргидрина путем конверсии полигидроксилированных алифатических углеводородов
WO2011096990A3 (fr) Catalyseur et procédé de déshydrogénation
WO2008151273A3 (fr) Systèmes de parfum
CL2013001127A1 (es) Composición que comprende penflufeno al menos un compuesto seleccionado entre el grupo de fenoles; uso de dichas composiciones para proteger materiales industriales frente al ataque y/o la destrucción por microorganismos; materiales industriales, en particular madera, un producto de madera para construcción o un compuesto de madera-plastico.
WO2009093817A3 (fr) Structure organométallique comprenant des nanoparticules métalliques et son utilisation comme matériau de stockage de gaz
UY35043A (es) Suspensión acuosa de material mineral reológicamente estable, método para su producción, partículas compuestas de material y uso de dicha suspensión
WO2010051327A3 (fr) Compositions azéotropes contenant du 1,1,2,3-tétrachloropropène et du fluorure d'hydrogène
RU2011134486A (ru) Агент, повышающий экспрессию редокс-факторов
WO2008138839A3 (fr) Procédé pour la préparation de principes actifs sur de l'eau thermale et compositions les comprenant
WO2013085897A3 (fr) Procédé pour réduire l'agglomération dans du plâtre de gypse ou des compositions de remplissage comprenant de l'éther de cellulose
WO2011156212A3 (fr) Procédé pour la dégradation des boues provenant de pâte à papier et de fabrication de papier
EP2255785A3 (fr) Préparation de type émulsion stable
NO20074491L (no) Sammensetning for avising og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application